Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Potential antiviral activities of chrysin against hepatitis B virus

Cytokines and Chemokines in HBV Infection

Antiviral Natural Products Against Chronic Hepatitis B: Recent Developments

Anti-hepatitis B virus activities of natural products and their antiviral mechanisms

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action

In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Development of novel therapeutics for chronic hepatitis B

Current trends and advances in antiviral therapy for chronic hepatitis B

Natural Products: Review for Their Effects of Anti-HBV

Functional cure of chronic hepatitis B:current status and perspectives

Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

Biological basis for functional cure of chronic hepatitis B

Novel therapeutic strategies for chronic hepatitis B

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

Interplay between hepatitis B virus and the type Ⅰ interferon system and new therapeutic strategies

Metabolites from traditional Chinese botanical drugs with anti-hepatitis B virus activity - a review

Emerging therapeutics and relevant targets for chronic Hepatitis B

Evaluation of Antiviral - Passive - Active Immunization ("sandwich") Therapeutic Strategy for Functional Cure of Chronic Hepatitis B in Mice.

Antiviral Activity of Chrysin against Influenza Virus Replication via Inhibition of Autophagy